CDEK
← All drugs Report issue

hrs-4642

Small moleculeexperimental

Clinical trial activity

15 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
14
Phase 3
1
Phase 4
0

Earliest trial started Sep 15, 2022 (NCT05533463)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07232875Phase 3Dec 31, 2025Hengrui Therapeutics, Inc.
NCT07296341Phase 1/Phase 2 (Phase 2)Dec 31, 2025Hengrui Therapeutics, Inc.
NCT07240766Phase 2Nov 15, 2025Zhejiang University
NCT07131514Phase 2Aug 31, 2025Hengrui Therapeutics, Inc., Jiao Tong University
NCT06955390Phase 1/Phase 2 (Phase 2)May 1, 2025Henan Medical University
NCT06938282Phase 2May 1, 2025Fudan University
NCT06770452Phase 2Feb 1, 2025Zhejiang University
NCT06773130Phase 1/Phase 2 (Phase 2)Jan 31, 2025Sichuan University
NCT06587061Phase 2Oct 31, 2024Hengrui Therapeutics, Inc., Jiao Tong University
NCT06620848Phase 2Oct 20, 2024Fudan University
NCT06547736Phase 2Sep 30, 2024Fudan University, Hengrui Therapeutics, Inc.
NCT06520488Phase 1/Phase 2 (Phase 2)Jul 31, 2024Hengrui Therapeutics, Inc.
NCT06385678Phase 1/Phase 2 (Phase 2)Jul 5, 2024Hengrui Therapeutics, Inc.
NCT06427239Phase 1/Phase 2 (Phase 2)May 29, 2024Fudan University, Hengrui Therapeutics, Inc.
NCT05533463Phase 1Sep 15, 2022Hengrui Therapeutics, Inc.
Showing 15 of 15 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hengrui Therapeutics, Inc.For profit9532022
Fudan UniversityAcademic/Hospital4412024
Jiao Tong UniversityAcademic/Hospital2212024
Zhejiang UniversityAcademic/Hospital2212025
Henan Medical UniversityAcademic/Hospital1112025
Sichuan UniversityAcademic/Hospital1112025
6 organizations
Page 1 / 1